Jean Paul Gagnon
Aventis Pharma
New chemical entityOutcomes researchPopulationDrug developmentMedicine
What is this?
Publications 2
#1Michael Dickson (USC: University of South Carolina)H-Index: 13
#2Jean Paul Gagnon (Aventis Pharma)H-Index: 2
The development of a new drug requires a major investment of capital, human resources and technological expertise. It also requires strict compliance with regulations on testing and manufacturing standards before a new compound can be used in the general population. All these requirements contribute to the cost increases for new chemical entity (NCE) R&D. The central question raised by this trend is: who in the future will pay for new pharmaceutical R&D? With this question in mind, this article ...
267 CitationsSource
#1Nancy C. Santanello (USMA: United States Military Academy)H-Index: 12
#2Drew Baker (Pfizer)H-Index: 1
Last. Richard J. Willke (Pharmacia)H-Index: 25
view all 14 authors...
Abstract Introduction Health-related quality-of-life (HRQL) can be defined as the impact of disease and treatment across the physical, psychological, social and somatic domains of functioning and well-being. Health-related quality-of-life measures are included in clinical trials of drug treatment to assess the impact of therapy on the patient's functioning. HRQL guidance could allow for use of this data in drug labeling and promotion. Objectives The aim of our study was to provide recommendation...
30 CitationsSource